This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

ZAVICEFTA®: As effective as a carbapenem in hospitalised patients with aerobic Gram-negative cIAIs15, cUTIs16 or HAP, including VAP17 

Overall Risk Factors

HAP/VAP Patient Profile

cIAI Patient Profile

cUTI Patient Profile

In the face of growing antimicrobial resistance, treatment options are urgently needed for patients at risk of MDR Gram-negative infections7,8

Risk factors for MDR Gram-negative infections2-6

Identifying patients at risk of MDR Gram-negative infections is vital for appropriate selection of adequate, early antimicrobial therapy to reduce the risk of fatal outcomes.8​​​​​​​

Early adequate antibacterial therapy is crucial for patients with serious Gram-negative infections8,9

Failure to treat early and appropriately can lead to fatal outcomes in patients with serious Gram-negative infections.8,9*​​​​​​​*

Explore more

Learn about ZAVICEFTA dosing across patient populations, preparation & administration, and shelf life & storage.

Access dosing guide

Access results of ZAVICEFTA Phase III clinical trials in adult patients with cUTI, cIAI or HAP/VAP

View Phase III trial results


Footnotes:

​​​​​​​**Early treatment must consider patient risk factors as well as local epidemiology.8
*30-day mortality rate among patients with P. aeruginosa bacteraemia who received delayed effective antimicrobial therapy’.10
30-day mortality among 909 patients with BSIs caused by ESBL-producing K. pneumoniae (n=222) and E. coli (n=687). 11
28-day mortality among 205 patients with BSIs caused by carbapenemase-producing K. pneumoniae (KPC and/or VIM). 12
§30-day mortality among 40 patients with BSIs caused by OXA-48 -producing Enterobacteriaceae.13
IIOverall mortality among 53 patients with BSIs caused by KPC-producing K. pneumoniae.14

Abbreviations:

​​​​​​​cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; K. pneumoniae, Klebsiella pneumoniae;  MBL, metallo-β-lactamase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase; P. aeruginosa, Pseudomonas aeruginosa;  CrCl, creatinine clearance; AMR, Antimicrobial Resistance; CVC central venous catheter; ICU intensive care unit. AE, adverse event; CE, clinically evaluable; CI, confidence interval; cMITT, clinically modified intention-to-treat; TOC, test of cure;

References:
  1. ZAVICEFTA. Summary of Product Characteristics
  2. Bassetti M, et al. Exp Rev Anti Infect Ther 2017;15:55–65
  3. Miller BM, et al. Am J Infect Control 2016;44:134–7
  4. De Waele J, et al. Intensive Care Med 2018;44:189–96
  5. Albur M, et al. Ann Clin Microbiol Antimicrob 2016;15:23
  6. Harris AD, et al. Emerg Infect Dis 2007;13:1144–9
  7. Timsit JF, et al. Intensive Care Med 2019;45:172–89 
  8. Bonine NG, et al. Am J Med Sci 2019;357:102–10
  9. Raman G, et al. BMC Infect Dis 2015;15:395
  10. Kang CI, et al. Clin Infect Dis 2003;37:745–51
  11. Scheuherman O, et al. Infect Control Hosp Epidemiol 2018;39:660–7
  12. Daikos GL, et al. Antimicrob Agents Chemother 2014;58:2322–8
  13. Navarro-San Francisco C, et al. Clin Microbiol Infect 2012;19:E72–9
  14. Zarkotou O, et al. Clin Microbiol Infect 2011;17:1798–803
  15. Mazuski JE, et al. Clin Infect Dis 2016;62:1380–9
  16. Wagenlehner FM, et al. Clin Infect Dis 2016;63:754–62
  17. Torres A, et al. Lancet Infect Dis 2017;Epub
  18. Micek ST, et al. Crit Care 2015;19:219
  19. Sartelli M, et al. World J Emerg Surg 2017;12:22
  20. Flores-Mireles AL, et al. Nat Rev Microbiol 2015;13:269–84 
PP-ZVA-GBR-0840. June 2021

Learn more about the tolerability data of ZAVICEFTA from four phase III clinical trials.

The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

View safety profile

** This is an optional area where footnotes can live.

KOL Video 2019

Professor Francesco G. De Rosa, Prof. of Infectious Diseases (Italy, Professor Philip Montravers, Anaestheisa and Critical Care Medicine (France) and Dr Paula Ramirez, Critical Care Department (Spain) discuss high-risk patients and early treatment of patients with suspected MDR Gram-negative infections in their clinical practice, and their experience using ZAVICEFTA. 

Card CTA

** This is an optional area where footnotes can live.

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No